The MADD Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line, harboring a targeted disruption of the MADD gene. This loss-of-function model enables dissection of MADD-dependent signaling without residual gene expression. The polyclonal format provides a heterogeneous pool of knockout cells, ensuring robust representation of independent editing events. These cells are ideal for functional genomics and pathway analysis in a hematopoietic context.
Raji is a widely used human Burkitt??s lymphoma-derived B lymphocyte cell line, retaining key features of mature B cells. It is a suspension line extensively employed in studies of B-cell receptor signaling, apoptosis, and lymphomagenesis. Its stable growth and well-defined genetic background make it suitable for generating knockout models to dissect signaling networks governing lymphocyte fate. As a model for B-cell malignancies, Raji cells provide a clinically relevant platform for investigating oncogenic pathways, including TNF-mediated responses.
MADD is a pivotal adaptor protein linking TNFR1 to MAP kinase and NF-??B activation. Upon TNF-alpha binding, MADD is recruited to the receptor complex through interactions with TRADD and TRAF2, where it scaffolds activation of ERK1/2, JNK, and p38 kinases and the IKK/NF-??B pathway. MADD also binds FADD and RIPK1, positioning it at a decision point between cell survival and apoptosis. Mechanistically, MADD promotes MAP3K-mediated phosphorylation cascades through MAP2Ks to effector MAPKs, while facilitating NF-??B transcriptional responses that oppose caspase-8-dependent apoptosis.
In the Raji B-cell lymphoma context, MADD knockout provides a powerful system to study the role of TNFR1 adaptors in malignant lymphocyte signaling. Aberrant TNF pathway activity is linked to lymphoma progression and drug resistance, highlighting MADD as a potential therapeutic target. Eliminating MADD enables researchers to examine signaling rewiring and reliance on alternative adaptors for survival. These cells are particularly suited for comparative analyses of TNF-induced NF-??B and MAPK activation, apoptosis resistance mechanisms, and target validation in B-cell malignancies.
These knockout cells support diverse assays, including Western blot to verify MADD loss and phosphorylation states of ERK, JNK, and p38 after TNF-alpha stimulation. Flow cytometry with Annexin V allows apoptosis quantification, while NF-??B reporter assays measure transcriptional activity. Co-immunoprecipitation probes TNFR1 complex composition without MADD. This model is thus essential for investigating TNF signaling in B-cell lymphoma, exploring apoptosis regulation, and validating MADD-centric therapeutic strategies. For further information, contact Ascent Research.
